Advertisement

Steroid-resistant rejection in kidney-transplanted patients: is ATG treatment for three or ten days preferable?

  • Michael Olausson
  • Lars Mjörnstedt
  • Hans Brynger
  • Ingemar Blohmé
Conference paper

Abstract

We carried out a randomized prospective trial to compare a 3-day with a 10-day course of antithymocyte globulin (ATG)- (Fresenius) for treatment of steroid-resistant rejection after renal transplantation. The aim was to study whether a short 3-day course was as safe and effective as the longer 10-day treatment. Thirty patients over a 3-year period were included. Patients that did not respond to treatment after 3 days received additional ATG from day 5 to day 10. The graft survival and the proportion of rejections reversed with the treatment were compared. Fifty percent responded promptly in the 3-day group and a further 29% after additional treatment. In the 10-day group, 62% reponded to the treatment. There was no significant difference between the groups. We, therefore, suggest that the standard antirejection treatment with ATG could be shortened without an increased risk of graft failure.

Key words

ATG Steroid-resistant rejection Kidney transplantation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Neuhaus P, Bechstein WO, Blumhardt G, Wiens M, Lemmens P, Langrehr JM, Lohmann R, Steffen R, Schlag H, Slama K-J, Lobeck H (1993) Comparison of quadruple immunosuppression after liver transplantation with ATG or IL-2 receptor antibody. Transplantation 55: 1320–1327PubMedCrossRefGoogle Scholar
  2. 2.
    Steininger R, Mühlbacher F, Hamilton G, Längle F, Gnant M, Popow T, Sautner T, Götzinger P, Wamser P, Stockenhuber F, Mirza D, Piza F (1991) Comparison of CyA, OKT3, and ATG immunoprophylaxis in human liver transplantation. Transplant Proc 23: 2269–2271PubMedGoogle Scholar
  3. 3.
    Birkeland SA (1975) A controlled clinical trial of treatment with ALG on established rejection of renal allografts. Acta Med Scand 198: 489PubMedCrossRefGoogle Scholar
  4. 4.
    Abouna GM, Al-Abdullah IH, Kelly-Sullivan D, Kumar MSA, Loose J, Phillips K, Yost S, Seirka D (1995) Randomized clinical trial of antithymocyte globulin induction in renal transplantation comparing a fixed daily dose with dose adjustment according to T cell monitoring. Transplantation 59: 1564–1568PubMedGoogle Scholar
  5. 5.
    Bock HA, Gallati H, Zürcher RM, Bachofen M, Mihatsch MJ, Landman J, Thiel G (1995) A randomized prospective trial of prophylactic immunosuppression with ATG-Fresenius versus OKT3 after renal transplantation. Transplantation 59: 830–840PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • Michael Olausson
    • 1
  • Lars Mjörnstedt
    • 1
  • Hans Brynger
    • 1
  • Ingemar Blohmé
    • 1
  1. 1.Department of Surgery, Division of Transplantation, Liver and Vascular SurgerySahlgrenska University HospitalGöteborgSweden

Personalised recommendations